PHARMACEUTICAL KIT FOR COMBINATION THERAPY OF COVID-19 (SARS-COV-2) AND METHOD OF ITS APPLICATION Russian patent published in 2021 - IPC A61K38/17 A61K31/495 A61P31/14 

FIELD: pharmaceutical industry; medicine.

SUBSTANCE: group of inventions relates to the pharmaceutical industry and medicine. Disclosed is a pharmaceutical kit for the combination therapy of COVID-19 (SARS-CoV-2). The pharmaceutical kit includes aprotinin (APR) in a therapeutically effective amount in the form of a finished medicinal product and favipiravir (FP) as a SARS-CoV-2 replication inhibitor in a therapeutically effective amount in the form of a finished medicinal product. The pharmaceutical kit ensures a therapeutically effective ratio of APR and the SARS-CoV-2 replication inhibitor placed in a package that protects the drugs from external factors. The pharmaceutical kit also includes instructions for use. Also disclosed is the use of the specified pharmaceutical kit for the combination therapy of COVID-19 (SARS-CoV-2).

EFFECT: group of inventions provides a synergistic effect in treatment of COVID-19 as well as decreased recovery time of a patient with COVID-19.

2 cl, 11 tbl, 4 ex